How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

A bag to collect forensic evidence is seen as the New York City Office of Chief Medical Examiner hosts DNA Extraction demonstration to unveil groundbreaking technology allowing OCME to test degraded ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

A FOX News original, Gallagher joined FNC at the network’s launch in 1996 and has covered breaking news stories throughout the past 26 years. On Inauguration Day 2025, he contributed to the extensive ...

Jeff Dean, who for years was one of Google’s most important executives, is leading the new artificial intelligence company with the backing of Google. By Cade Metz Reporting from Palo Alto, Calif.

Researchers have demonstrated for the first time that AI-assisted code can silently rewrite the digital files produced by the forensic DNA machines used in crime labs — the same computerized scan ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...